P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Recruiting now

Conditions studied: Helicobacter Pylori Infection

In brief

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.

Key facts

Study ID

NCT07285096

Run by

Yueyue Li

People needed

1730

Starts

2025-12-16

Expected to finish

2026-08-01

Last updated by the study team

2025-12-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients aged 18-70 years, regardless of gender;
• willing to receive H. pylori eradication therapy;
• diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

You may not qualify if…

• patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
• patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Where it is running

• Qilu Hospital of Shandong University — Jinan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.